Immunogenetics of CD4 lymphocyte count recovery during antiretroviral therapy: An AIDS clinical trials group study

David W. Haas, Daniel E. Geraghty, Janet Andersen, Jessica Mar, Alison A. Motsinger, Richard T. D'Aquila, Derya Unutmaz, Constance A. Benson, Marylyn D. Ritchie, Alan Landay

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

During antiretroviral therapy, CD4 lymphocyte count increases are modest in some patients despite virologic control. We explored whether polymorphisms in genes important for T cell expansion, survival, and apoptosis are associated with the magnitude of CD4 lymphocyte count recovery during antiretroviral therapy. We studied treatment-naive individuals who achieved sustained control of plasma viremia (<400 HIV-1 RNA copies/mL) for at least 48 weeks after initiation of antiretroviral therapy and compared genotypes among individuals who had an increase of either <200 or ≥200 CD4 cells/mm3 from baseline. A total of 137 single-nucleotide polymorphisms across 17 genes were characterized in 873 study participants. In multivariate analyses that controlled for clinical variables, polymorphisms in genes encoding tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), TNF-α, Bcl-2-interacting molecule (Bim), interleukin (IL)-15, and IL-15 receptor a chain (IL-15Rα) were associated with the magnitude of the increase in CD4 lymphocyte count, as were haplotypes in genes encoding interferon-α, IL-2, and IL-15Rα- (P<.05, for each). Multifactor dimensionality reduction identified a gene-gene interaction between IL-2/IL-15 receptor common β chain and IL-2/IL-7/IL-15 receptor common γ chain. Immune recovery during antiretroviral therapy is a complex phenotype that is influenced by multiple genetic variants. Future studies should validate these tentative associations and define underlying mechanisms.

Original languageEnglish (US)
Pages (from-to)1098-1107
Number of pages10
JournalJournal of Infectious Diseases
Volume194
Issue number8
DOIs
StatePublished - Oct 15 2006
Externally publishedYes

Fingerprint

Immunogenetics
CD4 Lymphocyte Count
Interleukin-15 Receptors
Acquired Immunodeficiency Syndrome
Clinical Trials
Genes
Interleukin-2
Multifactor Dimensionality Reduction
Therapeutics
Tumor Necrosis Factor-alpha
Apoptosis
Interleukin-15
Interleukin-7
Interleukins
Viremia
Haplotypes
Interferons
Single Nucleotide Polymorphism
HIV-1
Cell Survival

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Haas, D. W., Geraghty, D. E., Andersen, J., Mar, J., Motsinger, A. A., D'Aquila, R. T., ... Landay, A. (2006). Immunogenetics of CD4 lymphocyte count recovery during antiretroviral therapy: An AIDS clinical trials group study. Journal of Infectious Diseases, 194(8), 1098-1107. https://doi.org/10.1086/507313

Immunogenetics of CD4 lymphocyte count recovery during antiretroviral therapy : An AIDS clinical trials group study. / Haas, David W.; Geraghty, Daniel E.; Andersen, Janet; Mar, Jessica; Motsinger, Alison A.; D'Aquila, Richard T.; Unutmaz, Derya; Benson, Constance A.; Ritchie, Marylyn D.; Landay, Alan.

In: Journal of Infectious Diseases, Vol. 194, No. 8, 15.10.2006, p. 1098-1107.

Research output: Contribution to journalArticle

Haas, DW, Geraghty, DE, Andersen, J, Mar, J, Motsinger, AA, D'Aquila, RT, Unutmaz, D, Benson, CA, Ritchie, MD & Landay, A 2006, 'Immunogenetics of CD4 lymphocyte count recovery during antiretroviral therapy: An AIDS clinical trials group study', Journal of Infectious Diseases, vol. 194, no. 8, pp. 1098-1107. https://doi.org/10.1086/507313
Haas, David W. ; Geraghty, Daniel E. ; Andersen, Janet ; Mar, Jessica ; Motsinger, Alison A. ; D'Aquila, Richard T. ; Unutmaz, Derya ; Benson, Constance A. ; Ritchie, Marylyn D. ; Landay, Alan. / Immunogenetics of CD4 lymphocyte count recovery during antiretroviral therapy : An AIDS clinical trials group study. In: Journal of Infectious Diseases. 2006 ; Vol. 194, No. 8. pp. 1098-1107.
@article{cb4815f21c7248058820c2160e5c755e,
title = "Immunogenetics of CD4 lymphocyte count recovery during antiretroviral therapy: An AIDS clinical trials group study",
abstract = "During antiretroviral therapy, CD4 lymphocyte count increases are modest in some patients despite virologic control. We explored whether polymorphisms in genes important for T cell expansion, survival, and apoptosis are associated with the magnitude of CD4 lymphocyte count recovery during antiretroviral therapy. We studied treatment-naive individuals who achieved sustained control of plasma viremia (<400 HIV-1 RNA copies/mL) for at least 48 weeks after initiation of antiretroviral therapy and compared genotypes among individuals who had an increase of either <200 or ≥200 CD4 cells/mm3 from baseline. A total of 137 single-nucleotide polymorphisms across 17 genes were characterized in 873 study participants. In multivariate analyses that controlled for clinical variables, polymorphisms in genes encoding tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), TNF-α, Bcl-2-interacting molecule (Bim), interleukin (IL)-15, and IL-15 receptor a chain (IL-15Rα) were associated with the magnitude of the increase in CD4 lymphocyte count, as were haplotypes in genes encoding interferon-α, IL-2, and IL-15Rα- (P<.05, for each). Multifactor dimensionality reduction identified a gene-gene interaction between IL-2/IL-15 receptor common β chain and IL-2/IL-7/IL-15 receptor common γ chain. Immune recovery during antiretroviral therapy is a complex phenotype that is influenced by multiple genetic variants. Future studies should validate these tentative associations and define underlying mechanisms.",
author = "Haas, {David W.} and Geraghty, {Daniel E.} and Janet Andersen and Jessica Mar and Motsinger, {Alison A.} and D'Aquila, {Richard T.} and Derya Unutmaz and Benson, {Constance A.} and Ritchie, {Marylyn D.} and Alan Landay",
year = "2006",
month = "10",
day = "15",
doi = "10.1086/507313",
language = "English (US)",
volume = "194",
pages = "1098--1107",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - Immunogenetics of CD4 lymphocyte count recovery during antiretroviral therapy

T2 - An AIDS clinical trials group study

AU - Haas, David W.

AU - Geraghty, Daniel E.

AU - Andersen, Janet

AU - Mar, Jessica

AU - Motsinger, Alison A.

AU - D'Aquila, Richard T.

AU - Unutmaz, Derya

AU - Benson, Constance A.

AU - Ritchie, Marylyn D.

AU - Landay, Alan

PY - 2006/10/15

Y1 - 2006/10/15

N2 - During antiretroviral therapy, CD4 lymphocyte count increases are modest in some patients despite virologic control. We explored whether polymorphisms in genes important for T cell expansion, survival, and apoptosis are associated with the magnitude of CD4 lymphocyte count recovery during antiretroviral therapy. We studied treatment-naive individuals who achieved sustained control of plasma viremia (<400 HIV-1 RNA copies/mL) for at least 48 weeks after initiation of antiretroviral therapy and compared genotypes among individuals who had an increase of either <200 or ≥200 CD4 cells/mm3 from baseline. A total of 137 single-nucleotide polymorphisms across 17 genes were characterized in 873 study participants. In multivariate analyses that controlled for clinical variables, polymorphisms in genes encoding tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), TNF-α, Bcl-2-interacting molecule (Bim), interleukin (IL)-15, and IL-15 receptor a chain (IL-15Rα) were associated with the magnitude of the increase in CD4 lymphocyte count, as were haplotypes in genes encoding interferon-α, IL-2, and IL-15Rα- (P<.05, for each). Multifactor dimensionality reduction identified a gene-gene interaction between IL-2/IL-15 receptor common β chain and IL-2/IL-7/IL-15 receptor common γ chain. Immune recovery during antiretroviral therapy is a complex phenotype that is influenced by multiple genetic variants. Future studies should validate these tentative associations and define underlying mechanisms.

AB - During antiretroviral therapy, CD4 lymphocyte count increases are modest in some patients despite virologic control. We explored whether polymorphisms in genes important for T cell expansion, survival, and apoptosis are associated with the magnitude of CD4 lymphocyte count recovery during antiretroviral therapy. We studied treatment-naive individuals who achieved sustained control of plasma viremia (<400 HIV-1 RNA copies/mL) for at least 48 weeks after initiation of antiretroviral therapy and compared genotypes among individuals who had an increase of either <200 or ≥200 CD4 cells/mm3 from baseline. A total of 137 single-nucleotide polymorphisms across 17 genes were characterized in 873 study participants. In multivariate analyses that controlled for clinical variables, polymorphisms in genes encoding tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), TNF-α, Bcl-2-interacting molecule (Bim), interleukin (IL)-15, and IL-15 receptor a chain (IL-15Rα) were associated with the magnitude of the increase in CD4 lymphocyte count, as were haplotypes in genes encoding interferon-α, IL-2, and IL-15Rα- (P<.05, for each). Multifactor dimensionality reduction identified a gene-gene interaction between IL-2/IL-15 receptor common β chain and IL-2/IL-7/IL-15 receptor common γ chain. Immune recovery during antiretroviral therapy is a complex phenotype that is influenced by multiple genetic variants. Future studies should validate these tentative associations and define underlying mechanisms.

UR - http://www.scopus.com/inward/record.url?scp=33749595954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749595954&partnerID=8YFLogxK

U2 - 10.1086/507313

DO - 10.1086/507313

M3 - Article

C2 - 16991084

AN - SCOPUS:33749595954

VL - 194

SP - 1098

EP - 1107

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 8

ER -